# EDGAR Filing Document

**Accession Number:** 0001885827
**File Stem:** 0000950170-23-000093
**Filing Date:** 2023-1
**Character Count:** 7752
**Document Hash:** 134df20e631eba869e759bfba5ef23ba
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-000093.hdr.sgml**: 20230104

**ACCESSION NUMBER**: 0000950170-23-000093

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230104

**FILED AS OF DATE**: 20230104

**DATE AS OF CHANGE**: 20230104

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Virax Biolabs Group Ltd
- **CENTRAL INDEX KEY:** 0001885827
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **IRS NUMBER:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41440
- **FILM NUMBER:** 23504365

**BUSINESS ADDRESS:**
- **STREET 1:** 30 BROADWICK STREET
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W1F 8LX
- **BUSINESS PHONE:** 44 020 7788 7414

**MAIL ADDRESS:**
- **STREET 1:** 30 BROADWICK STREET
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W1F 8LX

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Virax Biolabs (Cayman) Ltd
- **DATE OF NAME CHANGE:** 20210930

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER<br>PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of January 2023**

**Commission File Number: 001-41440**

**Virax Biolabs Group Limited** 

**(Registrant's Name)**

**30 Broadwick Street**

**London, W1F 8LX**

**United Kingdom**

**(Address of Principal Executive Offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

------

When used in this Form 6-K, unless otherwise indicated, the terms "**the Company**," "**Virax**," "**we**," "**us**" and "**our**" refer to Virax Biolabs Group Limited. and its subsidiaries.

**Information Contained in this Form 6-K Report**

On January 4, 2023, Virax Biolabs Group Limited issued a press release announcing the distribution of HPV test kits with shipments anticipated in Q1 of 2023 to markets accepting the CE mark, such as the European Union. The test kit covers 18 different genotypes of HPV, including type 53, which is higher risk and becoming increasingly prevalent. The specialized diagnostic kits can be found by contacting the Company's sales representatives.

A copy of the press release dated January 4, 2023 is included as Exhibit 99.1 to this report.

**Exhibits**

---

| | |
|:---|:---|
| Exhibit No | Description |
| [<u>99.1</u>](vrax-ex99_1.htm) | [<u>Press Release dated January 4, 2023</u>](vrax-ex99_1.htm) |

---

------

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | VIRAX BIOLABS GROUP LIMITED |
| Date: | January 4, 2023 | By:  | /s/ James Foster |
|  |  |  | James Foster, Chief Executive Officer |

---

------

## Exhibit 99.1

Exhibit 99.1

Virax Biolabs Introduces Human Papillomavirus ("HPV") Test Kit

Kit Available Now for Distribution

LONDON, Jan. 4, 2023 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the distribution of HPV test kits with shipments anticipated in Q1 of 2023 to markets accepting the CE mark, such as the European Union. The test kit covers 18 different genotypes of HPV, including type 53, which is higher risk and becoming increasingly prevalent. The specialized diagnostic kits can be found by contacting the Company's sales representatives.

Virax's Chairman of the Board and Chief Executive Officer, James Foster commented "we are excited to expand our ViraxClear line of tests into an additional significant area of concern. These tests will cover more genotypes, have shorter processing times and lower costs than the currently available HPV tests in Europe. As we are able to supply around 200,000 of these tests per week, we have a significant opportunity to capture some market share."

HPV is one of the most prevalent sexually transmitted infections in the developed world. HPV is also the primary cause of cervical cancer in women with around 33,000 cases and 15,000 deaths annually in the EU, according to the European Centre for Disease Prevention and Control. Globally, HPV is estimated to cause over 600,000 cases of cervical cancer annually by the World Health Organization.

**About Virax Biolabs Group Limited**

Founded in 2013, Virax Biolabs is an Innovative Biotechnology company focused on the diagnosis of and the detection of immune responses to viral diseases.

In addition to distributing an array of viral test kits in unique geographies, Virax Biolabs Group Limited is currently developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing can be particularly effective in the management and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus. For more information, please visit www.viraxbiolabs.com.

**Safe Harbor Statement**

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability

------

to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

**Company Contact:**

Virax Biolabs Group Limited

Phone: +44 020 7788 7414

Email: <u>info@viraxbiolabs.com</u>

**Investor Relations Contact:**

Russo Partners, LLC

Maxim Jacobs, CFA

(646) 942-5591

Email: <u>Maxim.Jacobs@russopartnersllc.com</u>

SOURCE Virax Biolabs

------